



If a conflict arises between a Clinical Payment and Coding Policy (“CPCP”) and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. “Plan documents” include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. BCBSNM may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSNM has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act (“HIPAA”) approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing (“UB”) Editor, American Medical Association (“AMA”), Current Procedural Terminology (“CPT®”), CPT® Assistant, Healthcare Common Procedure Coding System (“HCPCS”), ICD-10 CM and PCS, National Drug Codes (“NDC”), Diagnosis Related Group (“DRG”) guidelines, Centers for Medicare and Medicaid Services (“CMS”) National Correct Coding Initiative (“NCCI”) Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Diagnostic Testing of Influenza

Policy Number: CPCPLAB033

Version 1.0

Enterprise Medical Policy Committee Approval Date: 1/25/2022

Plan Effective Date: May 1, 2022

Description

BCBSNM has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information:

1. One single rapid flu test—including either a point-of-contact rapid nucleic acid amplification test (NAAT) or a rapid antigen test—OR one single traditional NAAT in the outpatient setting for a patient in a single visit, but not both an antigen and NAAT for a single patient in a single visit, **may be reimbursable** for diagnosis of patients who present with signs and symptoms consistent with influenza disease (See Note 1 below) when influenza activity has been documented in the community or geographic area.

2. Viral culture testing for influenza in an outpatient setting **is not reimbursable**.
3. Outpatient influenza testing, including rapid antigen flu tests, rapid NAAT or RT-PCR tests, traditional RT-PCR tests, and viral culture testing **is not reimbursable** in asymptomatic patients.
4. Serology testing for influenza **is not reimbursable** under any circumstance.

Note 1: Typical Influenza Signs and Symptoms (CDC, 2020a)

- Fever: A 100.4°F or higher temperature or feeling feverish/chills AND one or more:
 - Cough
 - Sore throat
 - Headaches and/or body aches
 - Difficulty breathing or shortness of breath
 - Fatigue
 - Runny or stuffy nose

Procedure Codes

Codes
87804, 87400, 87501, 87502, 87503, 86710, 87275, 87276, 87631, 87632, 87633, 87254

References:

AAP. (2021). *Red Book® 2021-2024: Report of the Committee on Infectious Diseases, 32nd Edition*.

Abraham, M. K., Perkins, J., Vilke, G. M., & Coyne, C. J. (2016). Influenza in the Emergency Department: Vaccination, Diagnosis, and Treatment: Clinical Practice Paper Approved by American Academy of Emergency Medicine Clinical Guidelines Committee. *J Emerg Med, 50*(3), 536-542. doi:10.1016/j.jemermed.2015.10.013

Antoniol, S., Fidouh, N., Ghazali, A., Ichou, H., Bouzid, D., Kenway, P., . . . Casalino, E. (2018). Diagnostic performances of the Xpert® Flu PCR test and the OSOM® immunochromatographic rapid test for influenza A and B virus among adult patients in the Emergency Department. *J Clin Virol, 99-100*, 5-9. doi:10.1016/j.jcv.2017.12.005

Azar, M. M., & Landry, M. L. (2018). Detection of Influenza A and B Viruses and Respiratory Syncytial Virus by Use of Clinical Laboratory Improvement Amendments of 1988 (CLIA)-Waived Point-of-Care Assays: a Paradigm Shift to Molecular Tests. *J Clin Microbiol, 56*(7). doi:10.1128/jcm.00367-18

Brankston, G., Gitterman, L., Hirji, Z., Lemieux, C., & Gardam, M. (2007). Transmission of influenza A in human beings. *Lancet Infect Dis, 7*(4), 257-265. doi:10.1016/s1473-3099(07)70029-4

Call, S. A., Vollenweider, M. A., Hornung, C. A., Simel, D. L., & McKinney, W. P. (2005). Does this patient have influenza? *Jama*, 293(8), 987-997. doi:10.1001/jama.293.8.987

CDC. (2016, October 25). Rapid Influenza Diagnostic Tests. Retrieved from https://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm

CDC. (2017). Guidance for Clinicians on the Use of Rapid Influenza Diagnostic Tests. Retrieved from https://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm

CDC. (2019, March 4). Influenza virus testing in investigational outbreaks in institutional or other closed settings. Retrieved from <https://www.cdc.gov/flu/professionals/diagnosis/guide-virus-diagnostic-tests.htm>

CDC. (2020a, August 31). Algorithm to Assist in Medical Office Telephone Evaluation of Patients with Possible Influenza. Retrieved from <https://www.cdc.gov/flu/professionals/antivirals/office-evaluation.htm>

CDC. (2020b, September 1). Guide for considering influenza testing when influenza viruses are circulating in the community. Retrieved from <https://www.cdc.gov/flu/professionals/diagnosis/consider-influenza-testing.htm>

Chartrand, C., Leeflang, M. M., Minion, J., Brewer, T., & Pai, M. (2012). Accuracy of rapid influenza diagnostic tests: a meta-analysis. *Ann Intern Med*, 156(7), 500-511. doi:10.7326/0003-4819-156-7-201204030-00403

CMS. (2018, 01/04/2018). TESTS GRANTED WAIVED STATUS UNDER CLIA. Retrieved from <https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/waivetbl.pdf>

Cooper, N. J., Sutton, A. J., Abrams, K. R., Wailoo, A., Turner, D., & Nicholson, K. G. (2003). Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. *Bmj*, 326(7401), 1235. doi:10.1136/bmj.326.7401.1235

Cowling, B. J., Chan, K. H., Fang, V. J., Lau, L. L., So, H. C., Fung, R. O., . . . Peiris, J. S. (2010). Comparative epidemiology of pandemic and seasonal influenza A in households. *N Engl J Med*, 362(23), 2175-2184. doi:10.1056/NEJMoa0911530

Cox, N. J., & Subbarao, K. (1999). Influenza. *Lancet*, 354(9186), 1277-1282. doi:10.1016/s0140-6736(99)01241-6

Dobson, J., Whitley, R. J., Pocock, S., & Monto, A. S. (2015). Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. *Lancet*, 385(9979), 1729-1737. doi:10.1016/s0140-6736(14)62449-1

Dolin, R. (1976). Influenza: current concepts. *Am Fam Physician*, 14(3), 72-77. Retrieved from <http://dx.doi.org/>

Dolin, R. (2020, November 18). Seasonal influenza in adults: Transmission, clinical manifestations, and complications. *UpToDate*. Retrieved from <https://www.uptodate.com/contents/seasonal-influenza-in-adults-transmission-clinical-manifestations-and-complications>

Dolin, R. (2021, February 11). Diagnosis of seasonal influenza in adults. *UpToDate*. Retrieved from <https://www.uptodate.com/contents/diagnosis-of-seasonal-influenza-in-adults>

FDA. (2021, July 23). Devices@FDA. Retrieved from <https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm>

Harper, S. A., Bradley, J. S., Englund, J. A., File, T. M., Gravenstein, S., Hayden, F. G., . . . Zimmerman, R. K. (2009). Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. *Clin Infect Dis*, *48*(8), 1003-1032. doi:10.1086/598513

Hayden, F. G., Osterhaus, A. D., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., . . . Wightman, K. (1997). Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. *N Engl J Med*, *337*(13), 874-880. doi:10.1056/nejm199709253371302

Hazelton, B., Gray, T., Ho, J., Ratnamohan, V. M., Dwyer, D. E., & Kok, J. (2015). Detection of influenza A and B with the Alere i Influenza A & B: a novel isothermal nucleic acid amplification assay. *Influenza Other Respir Viruses*, *9*(3), 151-154. doi:10.1111/irv.12303

Heneghan, C. J., Onakpoya, I., Thompson, M., Spencer, E. A., Jones, M., & Jefferson, T. (2014). Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. *Bmj*, *348*, g2547. doi:10.1136/bmj.g2547

Hurt, A. C., Alexander, R., Hibbert, J., Deed, N., & Barr, I. G. (2007). Performance of six influenza rapid tests in detecting human influenza in clinical specimens. *J Clin Virol*, *39*(2), 132-135. doi:10.1016/j.jcv.2007.03.002

Ikenaga, M., Kosowska-Shick, K., Gotoh, K., Hidaka, H., Koga, H., Masunaga, K., . . . Matsuishi, T. (2008). Genotypes of macrolide-resistant pneumococci from children in southwestern Japan: raised incidence of strains that have both erm(B) and mef(A) with serotype 6B clones. *Diagn Microbiol Infect Dis*, *62*(1), 16-22. doi:10.1016/j.diagmicrobio.2007.10.013

Jefferson, T., Jones, M., Doshi, P., Spencer, E. A., Onakpoya, I., & Heneghan, C. J. (2014). Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. *Bmj*, *348*, g2545. doi:10.1136/bmj.g2545

Kanwar, N., Michael, J., Doran, K., Montgomery, E., & Selvarangan, R. (2020). Comparison of the ID Now Influenza A & B 2, Cobas Influenza A/B, and Xpert Xpress Flu Point-of-Care Nucleic Acid Amplification Tests for Influenza A/B Virus Detection in Children. *J Clin Microbiol*, *58*(3). doi:10.1128/jcm.01611-19

Kilbourne, E. D., & Loge, J. P. (1950). Influenza A prime: a clinical study of an epidemic caused by a new strain of virus. *Ann Intern Med*, *33*(2), 371-379. Retrieved from <http://dx.doi.org/>

Kux, L. (2017). *Microbiology Devices; Reclassification of Influenza Virus Antigen Detection Test Systems Intended for Use Directly With Clinical Specimens*. (FDA-2014-N-0440). Washington, D.C.: Federal Register Retrieved from <https://www.gpo.gov/fdsys/pkg/FR-2017-01-12/pdf/2017-00199.pdf>

- Lee, J. J., Verbakel, J. Y., Goyder, C. R., Ananthakumar, T., Tan, P. S., Turner, P. J., . . . Van den Bruel, A. (2019). The Clinical Utility of Point-of-Care Tests for Influenza in Ambulatory Care: A Systematic Review and Meta-analysis. *Clin Infect Dis*, *69*(1), 24-33. doi:10.1093/cid/ciy837
- Ling, L., Kaplan, S. E., Lopez, J. C., Stiles, J., Lu, X., & Tang, Y. W. (2018). Parallel Validation of Three Molecular Devices for Simultaneous Detection and Identification of Influenza A and B and Respiratory Syncytial Viruses. *J Clin Microbiol*, *56*(3). doi:10.1128/jcm.01691-17
- Loeb, M., Singh, P. K., Fox, J., Russell, M. L., Pabbaraju, K., Zarra, D., . . . Fonseca, K. (2012). Longitudinal study of influenza molecular viral shedding in Hutterite communities. *J Infect Dis*, *206*(7), 1078-1084. doi:10.1093/infdis/jis450
- Lopez Roa, P., Catalan, P., Giannella, M., Garcia de Viedma, D., Sandonis, V., & Bouza, E. (2011). Comparison of real-time RT-PCR, shell vial culture, and conventional cell culture for the detection of the pandemic influenza A (H1N1) in hospitalized patients. *Diagn Microbiol Infect Dis*, *69*(4), 428-431. doi:10.1016/j.diagmicrobio.2010.11.007
- Melchers, W. J. G., Kuijpers, J., Sickler, J. J., & Rahamat-Langendoen, J. (2017). Lab-in-a-tube: Real-time molecular point-of-care diagnostics for influenza A and B using the cobas(R) Liat(R) system. *J Med Virol*, *89*(8), 1382-1386. doi:10.1002/jmv.24796
- Miller, J. M., Binnicker, M. J., Campbell, S., Carroll, K. C., Chapin, K. C., Gilligan, P. H., . . . Yao, J. D. (2018). A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. *Clinical Infectious Diseases*, ciy381-ciy381. doi:10.1093/cid/ciy381
- Moesker, F. M., van Kampen, J. J. A., Aron, G., Schutten, M., van de Vijver, D., Koopmans, M. P. G., . . . Fraaij, P. L. A. (2016). Diagnostic performance of influenza viruses and RSV rapid antigen detection tests in children in tertiary care. *J Clin Virol*, *79*, 12-17. doi:10.1016/j.jcv.2016.03.022
- Mubareka, S., Lowen, A. C., Steel, J., Coates, A. L., Garcia-Sastre, A., & Palese, P. (2009). Transmission of influenza virus via aerosols and fomites in the guinea pig model. *J Infect Dis*, *199*(6), 858-865. Retrieved from <http://dx.doi.org/>
- Nicholson, K. G. (1992). Clinical features of influenza. *Semin Respir Infect*, *7*(1), 26-37. Retrieved from <http://dx.doi.org/>
- Nicholson, K. G., Aoki, F. Y., Osterhaus, A. D., Trottier, S., Carewicz, O., Mercier, C. H., . . . Ward, P. (2000). Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. *Lancet*, *355*(9218), 1845-1850. Retrieved from <http://dx.doi.org/>
- NIH. (2017). Influenza Diagnosis. Retrieved from <https://www.niaid.nih.gov/diseases-conditions/influenza-diagnosis>
- Ryu, S. W., Lee, J. H., Kim, J., Jang, M. A., Nam, J. H., Byoun, M. S., & Lim, C. S. (2016). Comparison of two new generation influenza rapid diagnostic tests with instrument-based digital readout systems for influenza virus detection. *Br J Biomed Sci*, *73*(3), 115-120. doi:10.1080/09674845.2016.1189026

Ryu, S. W., Suh, I. B., Ryu, S. M., Shin, K. S., Kim, H. S., Kim, J., . . . Lee, J. H. (2018). Comparison of three rapid influenza diagnostic tests with digital readout systems and one conventional rapid influenza diagnostic test. *J Clin Lab Anal*, 32(2). doi:10.1002/jcla.22234

Sintchenko, V., Gilbert, G. L., Coiera, E., & Dwyer, D. (2002). Treat or test first? Decision analysis of empirical antiviral treatment of influenza virus infection versus treatment based on rapid test results. *J Clin Virol*, 25(1), 15-21. Retrieved from <http://dx.doi.org/>

Uyeki, T. M., Bernstein, H. H., Bradley, J. S., Englund, J. A., File, T. M., Jr., Fry, A. M., . . . Pavia, A. T. (2018). Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. *Clinical Infectious Diseases*, 68(6), e1-e47. doi:10.1093/cid/ciy866

Yoon, J., Yun, S. G., Nam, J., Choi, S. H., & Lim, C. S. (2017). The use of saliva specimens for detection of influenza A and B viruses by rapid influenza diagnostic tests. *J Virol Methods*, 243, 15-19. doi:10.1016/j.jviromet.2017.01.013

Young, S., Illescas, P., Nicasio, J., & Sickler, J. J. (2017). Diagnostic accuracy of the real-time PCR cobas((R)) Liat((R)) Influenza A/B assay and the Alere i Influenza A&B NEAR isothermal nucleic acid amplification assay for the detection of influenza using adult nasopharyngeal specimens. *J Clin Virol*, 94, 86-90. doi:10.1016/j.jcv.2017.07.012

Zachary, K. (2020). Treatment of seasonal influenza in adults - UpToDate. In A. Thorner (Ed.), *UpToDate*. Retrieved from https://www.uptodate.com/contents/treatment-of-seasonal-influenza-in-adults?source=search_result&search=flu&selectedTitle=1~150

Policy Update History:

5/1/2022	New policy
----------	------------